Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Continuing its acquisition spree, Actavis will pay roughly $460 million to buy Auden Mckenzie, a generic drug firm headquartered in London. By adding about 175 generic and branded products to its portfolio, the deal puts Actavis in the lead in the U.K. generics market. Since 2012, when it merged with Watson Pharmaceuticals, Actavis has been aggressively establishing a position in specialty pharmaceuticals through a series of acquisitions. Subsequent deals included the $5 billion purchase of Warner Chilcott; $25 billion spent on Forest Laboratories; and, most recently, $66 billion paid for Allergan.
This article has been sent to the following recipient: